home / stock / bcyp / bcyp short
Short Information | SAB Biotherapeutics Inc Com (OTCMKTS:BCYP)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 121,447 |
Total Actual Volume | 260,269 |
Short Trends | |
---|---|
Cover Days | 2 |
Short Days | 10 |
No Change Days | 2 |
Averages | |
---|---|
Average Short Volume | 6,072 |
Average Short Percentage | 50.08% |
Is there a BCYP Short Squeeze or Breakout about to happen?
See the BCYP Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
12-04-2019 | $0.01 | $0.01 | $0.01 | $0.01 | 12,000 | 11,989 | 99.91% |
06-12-2019 | $0.032 | $0.032 | $0.032 | $0.032 | 10,060 | 10,000 | 99.4% |
05-29-2019 | $0.032 | $0.032 | $0.032 | $0.032 | 12,000 | 12,000 | 100% |
12-31-2018 | $0.048 | $0.04 | $0.048 | $0.04 | 23,842 | 4,639 | 19.46% |
12-10-2018 | $0.051 | $0.051 | $0.051 | $0.051 | 6,000 | 6,000 | 100% |
11-07-2018 | $0.051 | $0.05 | $0.051 | $0.05 | 8,213 | 4,553 | 55.44% |
09-21-2018 | $0.09775 | $0.09 | $0.09775 | $0.09 | 600 | 500 | 83.33% |
08-09-2018 | $0.053 | $0.053 | $0.053 | $0.053 | 4,200 | 3,000 | 71.43% |
07-25-2018 | $0.0668 | $0.036 | $0.0668 | $0.036 | 70,600 | 33,900 | 48.02% |
05-16-2018 | $0.065 | $0.06 | $0.065 | $0.06 | 5,594 | 5,000 | 89.38% |
04-10-2018 | $0.07 | $0.07 | $0.07 | $0.07 | 3,539 | 3,539 | 100% |
04-05-2018 | $0.07 | $0.07 | $0.07 | $0.07 | 11,267 | 11,267 | 100% |
03-26-2018 | $0.07 | $0.07 | $0.094 | $0.07 | 42,800 | 15,000 | 35.05% |
03-21-2018 | $0.071 | $0.045 | $0.071 | $0.045 | 49,554 | 60 | 0.12% |
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc Com Company Name:
BCYP Stock Symbol:
OTCMKTS Market:
SAB Biotherapeutics Inc Com Website:
SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human...
SAB highlights results from GLP toxicology study confirming SAB-142's mechanism of action at the 23rd Federation of Clinical Immunology Societies (FOCIS) Study shows SAB’s fully-human multi-target immune modulating therapeutic for treatment of Type 1 Diabetes is well tolerated ...
SIOUX FALLS, S.D., May 30, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies (fully-human polyc...